Albuplatin exhibited exceptional effects on survival of tumour-bearing mice compared to current clinical approved platinum-based therapy:
_.png)
Selection of Albuplatin acitivity experiments in vivo.
Why invest in Albuplatin?
-
The members of P4 Therapeutics combine interdisciplinary expertise in preclinical anticancer research with long-term experience in business development and represent a professional and highly motivated team.
-
Renowned pharmacologists with long-standing experience in designing clinical studies together with leading oncologists from the General Hospital (AKH) of Vienna will design and conduct preclinical and clinical trials.
-
Scale-up synthesis and method evaluations available.
-
Tolerability proofed by toxicity data in mice and rats.
-
Strong patent situation: P4 Therapeutics holds exclusive rights on the technology (Markush structure patent); Patent status granted in US, MEX and EU (2020); AUS, CHN, JPN, IND (expected in 2021); ISR, SGP, CAN (after 2021).
P4 Therapeutics needs EUR 5.8 million to achieve break-even status in 2024.
These funds will be raised by milestone based investments as follows:
-
EUR 0.8 million from non-dilutive government grants and tax premiums completed
-
EUR 1.0 million from private equity funds raised in a planned Series A round to be completed by Q3/2021
-
EUR 4.0 million from private equity funds raised in a planned Series B round to be completed by Q1/2023
P4 Therapeutics offers the opportunity for an appealing investment case:
-
Investment of EUR 5.0 Mio based on an attractive company valuation
-
Expected significant leveraged by Austrian scientific research funds
-
Exponential value creation within a short time frame
-
Upside potential due to broad applicability of the technology
By 2024, on successful completion of its development milestones, P4 Therapeutics will offer its investors a multiple return opportunity by M&A or by out-licensing within the pharmaceutical industry.
Interested? Request our teaser deck here: office@p4-t.com